Loomis Sayles & CO L P Viridian Therapeutics, Inc.\De Transaction History
Loomis Sayles & CO L P
- $77.3 Billion
- Q2 2025
A detailed history of Loomis Sayles & CO L P transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Loomis Sayles & CO L P holds 1,338,472 shares of VRDN stock, worth $32.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,338,472
Previous 1,370,356
2.33%
Holding current value
$32.2 Million
Previous $18.5 Million
1.29%
% of portfolio
0.02%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
185Shares Held
83.1MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$129 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$117 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$115 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$108 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$107 Million7.39% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $960M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...